(WST) West Pharmaceutical - Ratings and Ratios
Vials, Stoppers, Seals, Syringes, Devices
WST EPS (Earnings per Share)
WST Revenue
Description: WST West Pharmaceutical
West Pharmaceutical Services Inc (NYSE:WST) is a leading global manufacturer of containment and delivery systems for injectable drugs and healthcare products. The company operates through two segments: Proprietary Products and Contract-Manufactured Products, catering to biologic, generic, and pharmaceutical drug companies, as well as medical device companies.
The Proprietary Products segment offers a range of innovative solutions, including custom stoppers and seals, syringe and cartridge components, and administration systems that enhance the safe delivery of injectable drugs. Notable products include Crystal Zenith, a cyclic olefin polymer used in vials, syringes, and cartridges, and self-injection devices. The companys focus on quality is evident in its provision of analytical lab services, regulatory expertise, and after-sales technical support.
From a financial perspective, West Pharmaceutical Services has demonstrated a strong track record of growth, with a Return on Equity (ROE) of 17.47%. To further evaluate the companys performance, key metrics to monitor include revenue growth, gross margin expansion, and operating cash flow generation. Additionally, investors may want to track the companys research and development (R&D) expenditure as a percentage of sales, as innovation is crucial in the healthcare industry.
Some key performance indicators (KPIs) to consider when evaluating West Pharmaceutical Services include: - Revenue growth rate: to assess the companys ability to expand its top line. - Operating margin: to evaluate the companys pricing power and cost management. - Debt-to-equity ratio: to assess the companys leverage and financial flexibility. - Days inventory outstanding (DIO): to monitor the companys inventory management efficiency. By analyzing these KPIs, investors can gain a deeper understanding of West Pharmaceutical Services financial health and growth prospects.
WST Stock Overview
| Market Cap in USD | 17,901m |
| Sub-Industry | Health Care Supplies |
| IPO / Inception | 1978-01-13 |
WST Stock Ratings
| Growth Rating | -25.8% |
| Fundamental | 71.8% |
| Dividend Rating | 52.9% |
| Return 12m vs S&P 500 | -26.6% |
| Analyst Rating | 4.69 of 5 |
WST Dividends
| Dividend Yield 12m | 0.42% |
| Yield on Cost 5y | 0.39% |
| Annual Growth 5y | 4.50% |
| Payout Consistency | 96.5% |
| Payout Ratio | 12.1% |
WST Growth Ratios
| Growth Correlation 3m | 81.4% |
| Growth Correlation 12m | -55.1% |
| Growth Correlation 5y | -24.3% |
| CAGR 5y | 0.07% |
| CAGR/Max DD 3y | 0.00 |
| CAGR/Mean DD 3y | 0.00 |
| Sharpe Ratio 12m | -0.42 |
| Alpha | 0.37 |
| Beta | 0.539 |
| Volatility | 38.52% |
| Current Volume | 515k |
| Average Volume 20d | 503.6k |
| Stop Loss | 248.9 (-3%) |
| Signal | 0.17 |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (487.7m TTM) > 0 and > 6% of Revenue (6% = 177.6m TTM) |
| FCFTA 0.09 (>2.0%) and ΔFCFTA -1.53pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 36.36% (prev 29.52%; Δ 6.84pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.17 (>3.0%) and CFO 676.7m > Net Income 487.7m (YES >=105%, WARN >=100%) |
| Net Debt (-206.4m) to EBITDA (760.4m) ratio: -0.27 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.78 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (72.8m) change vs 12m ago -1.22% (target <= -2.0% for YES) |
| Gross Margin 35.32% (prev 35.84%; Δ -0.52pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 79.54% (prev 82.45%; Δ -2.91pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 299.1 (EBITDA TTM 760.4m / Interest Expense TTM 2.00m) >= 6 (WARN >= 3) |
Altman Z'' 10.45
| (A) 0.27 = (Total Current Assets 1.68b - Total Current Liabilities 604.6m) / Total Assets 3.95b |
| (B) 1.05 = Retained Earnings (Balance) 4.14b / Total Assets 3.95b |
| warn (B) unusual magnitude: 1.05 — check mapping/units |
| (C) 0.16 = EBIT TTM 598.1m / Avg Total Assets 3.72b |
| (D) 3.98 = Book Value of Equity 4.07b / Total Liabilities 1.02b |
| Total Rating: 10.45 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 71.76
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 1.95% = 0.98 |
| 3. FCF Margin 11.62% = 2.91 |
| 4. Debt/Equity 0.08 = 2.50 |
| 5. Debt/Ebitda 0.29 = 2.43 |
| 6. ROIC - WACC (= 8.66)% = 10.83 |
| 7. RoE 17.66% = 1.47 |
| 8. Rev. Trend 37.09% = 2.78 |
| 9. EPS Trend -52.73% = -2.64 |
What is the price of WST shares?
Over the past week, the price has changed by +0.56%, over one month by +5.57%, over three months by +17.79% and over the past year by -12.99%.
Is West Pharmaceutical a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of WST is around 249.73 USD . This means that WST is currently overvalued and has a potential downside of -2.69%.
Is WST a buy, sell or hold?
- Strong Buy: 10
- Buy: 2
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the WST price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 316.4 | 23.3% |
| Analysts Target Price | 316.4 | 23.3% |
| ValueRay Target Price | 277 | 7.9% |
Last update: 2025-09-05 05:08
WST Fundamental Data Overview
CCE Cash And Equivalents = 509.7m USD (last quarter)
P/E Trailing = 37.3238
P/E Forward = 33.7838
P/S = 6.0473
P/B = 6.1115
P/EG = 3.1275
Beta = 1.049
Revenue TTM = 2.96b USD
EBIT TTM = 598.1m USD
EBITDA TTM = 760.4m USD
Long Term Debt = 202.6m USD (from longTermDebt, last quarter)
Short Term Debt = 20.9m USD (from shortTermDebt, last quarter)
Debt = 223.5m USD (Calculated: Short Term 20.9m + Long Term 202.6m)
Net Debt = -206.4m USD (from netDebt column, last quarter)
Enterprise Value = 17.62b USD (17.90b + Debt 223.5m - CCE 509.7m)
Interest Coverage Ratio = 299.1 (Ebit TTM 598.1m / Interest Expense TTM 2.00m)
FCF Yield = 1.95% (FCF TTM 344.0m / Enterprise Value 17.62b)
FCF Margin = 11.62% (FCF TTM 344.0m / Revenue TTM 2.96b)
Net Margin = 16.48% (Net Income TTM 487.7m / Revenue TTM 2.96b)
Gross Margin = 35.32% ((Revenue TTM 2.96b - Cost of Revenue TTM 1.91b) / Revenue TTM)
Tobins Q-Ratio = 4.33 (Enterprise Value 17.62b / Book Value Of Equity 4.07b)
Interest Expense / Debt = 0.04% (Interest Expense 100.0k / Debt 223.5m)
Taxrate = 17.91% (107.5m / 600.2m)
NOPAT = 491.0m (EBIT 598.1m * (1 - 17.91%))
Current Ratio = 2.78 (Total Current Assets 1.68b / Total Current Liabilities 604.6m)
Debt / Equity = 0.08 (Debt 223.5m / last Quarter total Stockholder Equity 2.93b)
Debt / EBITDA = 0.29 (Net Debt -206.4m / EBITDA 760.4m)
Debt / FCF = 0.65 (Debt 223.5m / FCF TTM 344.0m)
Total Stockholder Equity = 2.76b (last 4 quarters mean)
RoA = 12.34% (Net Income 487.7m, Total Assets 3.95b )
RoE = 17.66% (Net Income TTM 487.7m / Total Stockholder Equity 2.76b)
RoCE = 20.18% (Ebit 598.1m / (Equity 2.76b + L.T.Debt 202.6m))
RoIC = 16.56% (NOPAT 491.0m / Invested Capital 2.96b)
WACC = 7.90% (E(17.90b)/V(18.12b) * Re(8.0%)) + (D(223.5m)/V(18.12b) * Rd(0.04%) * (1-Tc(0.18)))
Shares Correlation 3-Years: -92.32 | Cagr: -0.35%
Discount Rate = 8.0% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 77.77% ; FCFE base≈349.2m ; Y1≈337.3m ; Y5≈333.7m
Fair Price DCF = 82.64 (DCF Value 5.94b / Shares Outstanding 71.9m; 5y FCF grow -4.67% → 3.0% )
EPS Correlation: -52.73 | EPS CAGR: -3.51% | SUE: 1.80 | # QB: 2
Revenue Correlation: 37.09 | Revenue CAGR: 4.08% | SUE: 2.04 | # QB: 1
Additional Sources for WST Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle